Shots:

• The P-III HLX02-BC01 study involves assessing HLX02 vs EU-sourced trastuzumab in combination with docetaxel in a 3wks. cycle for up to 1yr. in patients in a ratio (1:1) with HER2-positive recurrent/ mBC- prior not treated with systemic treatment  
• Results:  Per ITT set- ORR_wk24 (71.3% vs 71.4%); Per PP set- ORR_wk24 (74.2% vs 73.2%); All subgroup analyses showed no statistically significant differences in ORR between the treatment groups in all populations- demonstrating the equivalence in efficacy
• No difference between the two treatment groups in 2EPs- including CBR- DCR- DoR- PFS- and OS

­ Ref: Henlius | Image: Henlius